Table 5. Multivariable linear mixed effects analysis of heart rate after antimalarial treatment in children (age <12 years).
| Variable | Number of observations | Adjusted estimate (95% CI) | p-value |
|---|---|---|---|
| Change from baseline after ASAQ | 674 | −21.03 (−23.01 to −19.04) beats/minute | <0.001 |
| Change from baseline versus ASAQ, by antimalarial treatment arm | 3,151 | ||
| ASAQ | 674 | Reference | |
| DP | 1,131 | 3.87 (1.63 to 6.12) beats/minute | <0.001 |
| AL | 596 | 0.16 (−2.43 to 2.76) beats/minute | 0.9015 |
| PA | 750 | 8.33 (5.88 to 10.77) beats/minute | <0.001 |
| Baseline measurement versus ASAQ, by antimalarial treatment arm | 1,579 | ||
| ASAQ | 338 | Reference | |
| DP | 567 | −0.09 (−2.11 to 1.93) beats/minute | 0.9318 |
| AL | 299 | 0.59 (−1.92 to 3.10) beats/minute | 0.6433 |
| PA | 375 | −0.75 (−2.98 to 1.49) beats/minute | 0.5132 |
| Body temperature, per 1°C increase | 3,151 | 5.49 (4.91 to 6.07) beats/minute | <0.001 |
| Age, per 1-year increase | 3,151 | −3.77 (−3.99 to −3.55) beats/minute | <0.001 |
AL, artemether–lumefantrine; ASAQ, artesunate–amodiaquine; DP, dihydroartemisinin–piperaquine; PA, pyronaridine–artesunate.